Lord, Abbett & Co
TXG icon

Lord, Abbett & Co’s 10x Genomics TXG Stock Holding History

Lord, Abbett & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
397,868
+68,550
+21% +$1.8M 0.04% 337
2026
Q1 		$6.99M Buy
+329,318
New +$6.58M 0.02% 408
2024
Q1 		– Sell
-409,127
Closed -$22.9M – 586
2023
Q4 		$22.9M Sell
409,127
-365,959
-47% -$15.9M 0.08% 317
2023
Q3 		$32M Sell
775,086
-481,240
-38% -$25M 0.12% 240
2023
Q2 		$70.2M Buy
1,256,326
+206,237
+20% +$11.2M 0.24% 126
2023
Q1 		$58.6M Buy
+1,050,089
New +$49M 0.21% 156
2022
Q2 		– Sell
-59,159
Closed -$4.5M – 629
2022
Q1 		$4.5M Sell
59,159
-26,483
-31% -$2.32M 0.01% 555
2021
Q4 		$12.8M Buy
85,642
+36,403
+74% +$5.58M 0.03% 453
2021
Q3 		$7.17M Buy
49,239
+7,891
+19% +$1.35M 0.02% 562
2021
Q2 		$8.1M Sell
41,348
-320,798
-89% -$58.1M 0.02% 563
2021
Q1 		$65.5M Sell
362,146
-216,080
-37% -$37.3M 0.17% 193
2020
Q4 		$81.9M Buy
578,226
+81,421
+16% +$11.8M 0.22% 140
2020
Q3 		$61.9M Sell
496,805
-31,298
-6% -$3.29M 0.2% 160
2020
Q2 		$47.2M Sell
528,103
-260,988
-33% -$20.3M 0.17% 199
2020
Q1 		$49.2M Buy
789,091
+135,256
+21% +$10.6M 0.22% 139
2019
Q4 		$49.9M Sell
653,835
-79,289
-11% -$4.77M 0.17% 186
2019
Q3 		$36.9M Buy
+733,124
New +$40.6M 0.13% 277

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lord, Abbett & Co's TXG Position: Q2 2026 in Review

Lord, Abbett & Co increased its 10x Genomics (TXG) stake by 21% in Q2 2026, buying an estimated $1.8M and bringing the position to 397,868 shares worth $15.3M. The position accounts for 0.04% of the portfolio, ranked #337.

Lord, Abbett & Co first reported a position in TXG in Q3 2019 and has held it in 17 quarters since. The position peaked at $81.9M in Q4 2020. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Lord, Abbett & Co held 397,868 shares of 10x Genomics worth $15.3M as of Q2 2026.
  • Lord, Abbett & Co bought 68,550 10x Genomics shares in Q2 2026, an estimated $1.8M.
  • 10x Genomics made up 0.04% of Lord, Abbett & Co's portfolio in Q2 2026, its #337 holding.
  • Lord, Abbett & Co first reported a position in 10x Genomics in Q3 2019 and has held it in 17 quarters since.
  • Lord, Abbett & Co's 10x Genomics position peaked at $81.9M in Q4 2020.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.